Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Spine Corp V.ASG

Alternate Symbol(s):  ASAPF

Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. It offers a range of devices specifically designed to address cervical spine conditions and restore optimal functionality. Its Cervical product line includes apollo, Discovery, and DEXA-C. The apollo Anterior Cervical Plate system is comprised of cervical plates and bone screws constructed of titanium alloy as described by ASTM F136. Discovery is its Spine's invasive cervical interbody fusion system. The DEXA-C is crafted to mimic the lattice structure of cancellous bone in humans while maintaining a comparable modulus of elasticity. The Company has established a physician training program through national and regional cadaver labs.


TSXV:ASG - Post by User

Post by Topdog2022on Jun 06, 2022 8:39am
151 Views
Post# 34733465

Wonderful news for Aurora Spine

Wonderful news for Aurora SpineThis is great news for Aurora Spine.  Their DEXA-C cervical implant was rolled out in Q1 in a controlled rollout to 2 doctors.  The results from this DEXA-C Q1 slow rollout produced sales of approx $280k USD or 7.9% of entire company sales from their first ever quarter of sales.  DEXA-C is now being rolled out to 9 more doctors in Q2 as part of their secondary phased in rollout before full Alpha release.  Now that DEXA-L has been FDA approved I presume this device will be offered through the same channels.

The big news announcement will be when SILO TFX gets FDA approval which management believes will come sometime later this month.  This device is an industry game changer..  Why? A third party study completed of Silo TFX compared to the leading devices in this space from Medtronic and Si-Bone showed that SiLO TFX had 76% better fixation.  Also it only requires one incision versus three versus the competitors which means faster healing times.  
<< Previous
Bullboard Posts
Next >>